CHMP recommends AbbVie's HCV combo Maviret

EMA’s CHMP recommended approval of an MAA from AbbVie Inc. (NYSE:ABBV) for Maviret glecaprevir/pibrentasvir to treat chronic HCV infection in adults. Maviret is under Priority Review by FDA...